| Bioactivity | Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. |
| Name | Atreleuton |
| CAS | 154355-76-7 |
| Formula | C16H15FN2O2S |
| Molar Mass | 318.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc. [2]. Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. [3]. Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73. |
Atreleuton
CAS: 154355-76-7 F: C16H15FN2O2S W: 318.37
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (AB
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.